The triptans

References

• Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia8(Suppl. 7), 1–96 (1988).
   Web of Science ®Google Scholar
• Society. HCSotIH. The International Classification of Headache Disorders. 2nd Edition. Cephalalgia24, 1–149 (2004).
   Web of Science ®Google Scholar
• Lipton RB, Bigal ME, Diamond M et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology68, 343–349 (2007).
   PubMed Web of Science ®Google Scholar
• Stovner L, Hagen K, Jensen R et al. The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia27, 193–210 (2007).
   PubMed Web of Science ®Google Scholar
• Lipton RB, Diamond S, Reed M et al. Migraine diagnosis and treatment: results from the American Migraine Study II. Headache41, 638–645 (2001).
   PubMed Web of Science ®Google Scholar
• Edmeads J, Mackell JA. The economic impact of migraine: an analysis of direct and indirect costs. Headache42, 501–509 (2002).
   PubMed Web of Science ®Google Scholar
• Edmeads J. History of migraine treatment. Can. J. Clin. Pharmacol.6(Suppl. A), 5A–8A (1999).
   Google Scholar
• Silberstein SD. Clinical practice guidelines. Cephalalgia25, 765–766 (2005).
   PubMed Web of Science ®Google Scholar
• Rapoport AM, Tepper SJ, Bigal ME, Sheftell FD. The triptan formulations: how to match patients and products. CNS Drugs17, 431–447 (2003).
   PubMed Web of Science ®Google Scholar
• Humphrey PP, Feniuk W, Marriott AS et al. Preclinical studies on the anti-migraine drug, sumatriptan. Eur. Neurol.31, 282–290 (1991).
   PubMed Web of Science ®Google Scholar
• Lipton RB, Bigal ME, Rush SR et al. Migraine practice patterns among neurologists. Neurology62, 1926–1931 (2004).
   PubMed Web of Science ®Google Scholar
• Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet358, 1668–1675 (2001).
   PubMed Web of Science ®Google Scholar
• Rapoport AM, Tepper SJ, Sheftell FD et al. Which triptan for which patient? Neurol. Sci.27(Suppl. 2), S123–S129 (2006).
   PubMed Web of Science ®Google Scholar
• McCulloch J, Uddman R, Kingman TA, Edvinsson L. Calcitonin gene-related peptide: functional role in cerebrovascular regulation. Proc. Natl Acad. Sci. USA83, 5731–5735 (1986).
   PubMed Web of Science ®Google Scholar
• Gulbenkian S, Uddman R, Edvinsson L. Neuronal messengers in the human cerebral circulation. Peptides22, 995–1007 (2001).
   PubMed Web of Science ®Google Scholar
• Uddman R, Tajti J, Hou M et al. Neuropeptide expression in the human trigeminal nucleus caudalis and in the cervical spinal cord C1 and C2. Cephalalgia22, 112–116 (2002).
   PubMed Web of Science ®Google Scholar
• May A, Shepheard SL, Knorr M et al. Retinal plasma extravasation in animals but not in humans: implications for the pathophysiology of migraine. Brain121(Pt 7), 1231–1237 (1998).
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Hargreaves RJ. Mechanisms of action of serotonin 5-HT1B/D agonists: insights into migraine pathophysiology using rizatriptan. Neurology55, S8–S14 (2000).
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann. Neurol.33, 48–56 (1993).
   PubMed Web of Science ®Google Scholar
• Kaube H, Hoskin KL, Goadsby PJ. Activation of the trigeminovascular system by mechanical distension of the superior sagittal sinus in the cat. Cephalalgia12, 133–136 (1992).
   PubMed Web of Science ®Google Scholar
• Burstein R, Jakubowski M. Analgesic triptan action in an animal model of intracranial pain: a race against the development of central sensitization. Ann. Neurol.55, 27–36 (2004).
   PubMed Web of Science ®Google Scholar
• Burstein R, Levy D, Jakubowski M. Effects of sensitization of trigeminovascular neurons to triptan therapy during migraine. Rev. Neurol. (Paris).161, 658–660 (2005).
   PubMed Web of Science ®Google Scholar
• Moskowitz MA. Genes, proteases, cortical spreading depression and migraine: impact on pathophysiology and treatment. Funct. Neurol.22, 133–136 (2007).
   PubMed Web of Science ®Google Scholar
• Moskowitz MA, Cutrer FM. SUMATRIPTAN: a receptor-targeted treatment for migraine. Annu. Rev. Med.44, 145–154 (1993).
   PubMed Web of Science ®Google Scholar
• Hargreaves RJ. Pharmacology and potential mechanisms of action of rizatriptan. Cephalalgia20(Suppl. 1), 2–9 (2000).
   PubMedGoogle Scholar
• Humphrey PP, Feniuk W. Mode of action of the anti-migraine drug sumatriptan. Trends Pharmacol. Sci.12, 444–446 (1991).
   PubMed Web of Science ®Google Scholar
• Longmore J, Shaw D, Smith D et al. Differential distribution of 5HT1D- and 5HT1B-immunoreactivity within the human trigemino–cerebrovascular system: implications for the discovery of new antimigraine drugs. Cephalalgia17, 833–842 (1997).
   PubMed Web of Science ®Google Scholar
• Ma QP, Hill R, Sirinathsinghji D. Colocalization of CGRP with 5-HT1B/1D receptors and substance P in trigeminal ganglion neurons in rats. Eur. J. Neurosci.13, 2099–2104 (2001).
   PubMed Web of Science ®Google Scholar
• Ramadan NM. The link between glutamate and migraine. CNS Spectr.8, 446–449 (2003).
   PubMed Web of Science ®Google Scholar
• Panconesi A, Anselmi B, Curradi C et al. Comparison between venoconstrictor effects of sumatriptan and ergotamine in migraine patients. Headache34, 194–197 (1994).
   PubMed Web of Science ®Google Scholar
• Beer MS, Stanton JA, Bevan Y et al. L-694,247: a potent 5-HT1D receptor agonist. Br. J. Pharmacol.110, 1196–1200 (1993).
   PubMed Web of Science ®Google Scholar
• Williamson DJ, Shepheard SL, Hill RG, Hargreaves RJ. The novel anti-migraine agent rizatriptan inhibits neurogenic dural vasodilation and extravasation. Eur. J. Pharmacol.328, 61–64 (1997).
   PubMed Web of Science ®Google Scholar
• Mannix LK, Files JA. The use of triptans in the management of menstrual migraine. CNS Drugs19, 951–972 (2005).
   PubMed Web of Science ®Google Scholar
• Tfelt-Hansen P. Triptan medications to treat acute migraine. Lancet359, 1152–1153 (2002).
   PubMedGoogle Scholar
• Hargreaves R. New migraine and pain research. Headache47(Suppl. 1), S26–S43 (2007).
   PubMedGoogle Scholar
• Edvinsson L, Uddman E, Wackenfors A et al. Triptan-induced contractile (5-HT1B receptor) responses in human cerebral and coronary arteries: relationship to clinical effect. Clin. Sci. (Lond).109, 335–342 (2005).
   PubMed Web of Science ®Google Scholar
• Nilsson T, Longmore J, Shaw D et al. Characterisation of 5-HT receptors in human coronary arteries by molecular and pharmacological techniques. Eur. J. Pharmacol.372, 49–56 (1999).
   PubMed Web of Science ®Google Scholar
• Evers S, Husstedt IW, Enbergs A. Coronary angiography in migraine patient after subcutaneous sumatriptan. Lancet345, 198 (1995).
   PubMedGoogle Scholar
• Dodick D, Lipton RB, Martin V et al. Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine. Headache44, 414–425 (2004).
   PubMed Web of Science ®Google Scholar
• Ferrari MD, Loder E, McCarroll KA, Lines CR. Meta-analysis of rizatriptan efficacy in randomized controlled clinical trials. Cephalalgia21, 129–136 (2001).
   PubMed Web of Science ®Google Scholar
• Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology55, 754–762 (2000).
   PubMed Web of Science ®Google Scholar
• Wendt J, Cady R, Singer R et al. A randomized, double-blind, placebo-controlled trial of the efficacy and tolerability of a 4-mg dose of subcutaneous sumatriptan for the treatment of acute migraine attacks in adults. Clin. Ther.28, 517–526 (2006).
   PubMed Web of Science ®Google Scholar
• Dahlof C, Tfelt-Hansen P, Massiou H, Fazekas A. Dose finding, placebo-controlled study of oral almotriptan in the acute treatment of migraine. Neurology57, 1811–1817 (2001).
   PubMed Web of Science ®Google Scholar
• Dowson AJ, Massiou H, Lainez JM, Cabarrocas X. Almotriptan is an effective and well-tolerated treatment for migraine pain: results of a randomized, double-blind, placebo-controlled clinical trial. Cephalalgia22, 453–461 (2002).
   PubMed Web of Science ®Google Scholar
• Pascual J, Falk RM, Piessens F et al. Consistent efficacy and tolerability of almotriptan in the acute treatment of multiple migraine attacks: results of a large, randomized, double-blind, placebo-controlled study. Cephalalgia20, 588–596 (2000).
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Ferrari MD, Olesen J et al. Eletriptan in acute migraine: a double-blind, placebo-controlled comparison to sumatriptan. Eletriptan Steering Committee Neurology54, 156–163 (2000).
   PubMed Web of Science ®Google Scholar
• Sheftell F, Ryan R, Pitman V. Efficacy, safety, and tolerability of oral eletriptan for treatment of acute migraine: a multicenter, double-blind, placebo-controlled study conducted in the United States. Headache43, 202–213 (2003).
   PubMed Web of Science ®Google Scholar
• Stark R, Dahlof C, Haughie S, Hettiarachchi J. Efficacy, safety and tolerability of oral eletriptan in the acute treatment of migraine: results of a Phase III, multicentre, placebo-controlled study across three attacks. Cephalalgia22, 23–32 (2002).
   PubMed Web of Science ®Google Scholar
• Sakai F, Diener HC, Ryan R, Poole P. Eletriptan for the acute treatment of migraine: results of bridging a Japanese study to Western clinical trials. Curr. Med. Res. Opin.20, 269–277 (2004).
   PubMed Web of Science ®Google Scholar
• Rapoport A, Ryan R, Goldstein J, Keywood C. Dose range-finding studies with frovatriptan in the acute treatment of migraine. Headache42(Suppl. 2) S74–S83 (2002).
   PubMed Web of Science ®Google Scholar
• Goldstein J, Keywood C. Frovatriptan for the acute treatment of migraine: a dose-finding study. Headache42, 41–48 (2002).
   PubMed Web of Science ®Google Scholar
• Havanka H, Dahlof C, Pop PH et al. Efficacy of naratriptan tablets in the acute treatment of migraine: a dose-ranging study. Naratriptan S2WB2004 Study Group. Clin. Ther.22, 970–980 (2000).
   PubMed Web of Science ®Google Scholar
• Bomhof M, Paz J, Legg N et al. Comparison of rizatriptan 10 mg vs. naratriptan 2.5 mg in migraine. Eur. Neurol.42, 173–179 (1999).
   PubMed Web of Science ®Google Scholar
• Heywood J, Bomhof MA, Pradalier A et al. Tolerability and efficacy of naratriptan tablets in the acute treatment of migraine attacks for 1 year. Naratriptan Long-Term Study Group. Cephalalgia20, 470–474 (2000).
   PubMed Web of Science ®Google Scholar
• Ferrari MD. Rizatriptan: a new milestone in migraine treatment. Introduction. Cephalalgia20(Suppl. 1), 1 (2000).
   PubMedGoogle Scholar
• Goldberg MR, Lee Y, Vyas KP et al. Rizatriptan, a novel 5-HT1B/1D agonist for migraine: single- and multiple-dose tolerability and pharmacokinetics in healthy subjects. J. Clin. Pharmacol.40, 74–83 (2000).
   PubMed Web of Science ®Google Scholar
• Ahrens SP, Farmer MV, Williams DL et al. Efficacy and safety of rizatriptan wafer for the acute treatment of migraine. Rizatriptan Wafer Protocol 049 Study Group. Cephalalgia19, 525–530 (1999).
   PubMed Web of Science ®Google Scholar
• Klapper JA, O’Connor S. Rizatriptan wafer – sublingual vs. placebo at the onset of acute migraine. Cephalalgia20, 585–587 (2000).
   PubMed Web of Science ®Google Scholar
• Swan SK, Alcorn H Jr, Rodgers A et al. Pharmacokinetic profile of rizatriptan 10-mg tablet and 10-mg orally disintegrating tablet administered with or without water in healthy subjects: an open-label, randomized, single-dose, 3-period crossover study. J. Clin. Pharmacol.46, 172–178 (2006).
   PubMed Web of Science ®Google Scholar
• Carpay J, Schoenen J, Ahmad F et al. Efficacy and tolerability of sumatriptan tablets in a fast-disintegrating, rapid-release formulation for the acute treatment of migraine: results of a multicenter, randomized, placebo-controlled study. Clin. Ther.26, 214–223 (2004).
   PubMed Web of Science ®Google Scholar
• Gruffydd-Jones K, Hood CA, Price DB. A within-patient comparison of subcutaneous and oral sumatriptan in the acute treatment of migraine in general practice. Cephalalgia17, 31–36 (1997).
   PubMed Web of Science ®Google Scholar
• Carpay HA, Dowson AJ. Sumatriptan fast-disintegrating/rapid-release tablets: viewpoints. Drugs66, 891–892 (2006).
   PubMedGoogle Scholar
• Sheftell FD, Dahlof CG, Brandes JL et al. Two replicate randomized, double-blind, placebo-controlled trials of the time to onset of pain relief in the acute treatment of migraine with a fast-disintegrating/rapid-release formulation of sumatriptan tablets. Clin. Ther.27, 407–417 (2005).
   PubMed Web of Science ®Google Scholar
• Perry CM, Markham A. Sumatriptan. An updated review of its use in migraine. Drugs55, 889–922 (1998).
   PubMed Web of Science ®Google Scholar
• Diamond S. The use of sumatriptan in patients on monoamine oxidase inhibitors. Neurology45, 1039–1040 (1995).
   PubMed Web of Science ®Google Scholar
• Rapoport AM, Ramadan NM, Adelman JU et al. Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. A multicenter, double-blind, placebo-controlled, dose range-finding study. The 017 Clinical Trial Study Group. Neurology49, 1210–1218 (1997).
   PubMed Web of Science ®Google Scholar
• Dowson AJ, MacGregor EA, Purdy RA et al. Zolmitriptan orally disintegrating tablet is effective in the acute treatment of migraine. Cephalalgia22, 101–106 (2002).
   PubMed Web of Science ®Google Scholar
• Loder EW, Dowson AJ, Spierings EL. Part II: clinical efficacy and tolerability of zolmitriptan orally disintegrating tablet in the acute treatment of migraine. Curr. Med. Res. Opin.21(Suppl. 3), S8–S12 (2005).
   PubMed Web of Science ®Google Scholar
• Spierings EL, Rapoport AM, Dodick DW, Charlesworth B. Acute treatment of migraine with zolmitriptan 5 mg orally disintegrating tablet. CNS Drugs18, 1133–1141 (2004).
   PubMed Web of Science ®Google Scholar
• Steiner TJ, Diener HC, MacGregor EA et al. Comparative efficacy of eletriptan and zolmitriptan in the acute treatment of migraine. Cephalalgia23, 942–952 (2003).
   PubMed Web of Science ®Google Scholar
• Gruffyd-Jones K, Kies B, Middleton A et al. Zolmitriptan versus sumatriptan for the acute oral treatment of migraine: a randomized, double-blind, international study. Eur. J. Neurol.8, 237–245 (2001).
   PubMed Web of Science ®Google Scholar
• Gallagher RM, Dennish G, Spierings EL, Chitra R. A comparative trial of zolmitriptan and sumatriptan for the acute oral treatment of migraine. Headache40, 119–128 (2000).
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Massiou H, Pascual J et al. Almotriptan and zolmitriptan in the acute treatment of migraine. Acta Neurol. Scand.115, 34–40 (2007).
   PubMed Web of Science ®Google Scholar
• Dixon R, Gillotin C, Gibbens M et al. The pharmacokinetics and effects on blood pressure of multiple doses of the novel anti-migraine drug zolmitriptan (311C90) in healthy volunteers. Br J. Clin. Pharmacol.43, 273–281 (1997).
   PubMed Web of Science ®Google Scholar
• Rolan PE, Martin GR. Zolmitriptan: a new acute treatment for migraine. Expert Opin. Investig. Drugs7, 633–652 (1998).
   PubMedGoogle Scholar
• Boureau F, Kappos L, Schoenen J et al. A clinical comparison of sumatriptan nasal spray and dihydroergotamine nasal spray in the acute treatment of migraine. Int. J. Clin. Pract.54, 281–286 (2000).
   PubMed Web of Science ®Google Scholar
• Charlesworth BR, Dowson AJ, Purdy A et al. Speed of onset and efficacy of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double-blind, placebo-controlled, dose-ranging study versus zolmitriptan tablet. CNS Drugs17, 653–667 (2003).
   PubMed Web of Science ®Google Scholar
• Dodick D, Brandes J, Elkind A et al. Speed of onset, efficacy and tolerability of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double-blind, placebo-controlled study. CNS Drugs19, 125–136 (2005).
   PubMed Web of Science ®Google Scholar
• Gawel M, Aschoff J, May A, Charlesworth BR. Zolmitriptan 5 mg nasal spray: efficacy and onset of action in the acute treatment of migraine – results from Phase 1 of the REALIZE Study. Headache45, 7–16 (2005).
   PubMed Web of Science ®Google Scholar
• Krymchantowski AV, Bigal ME. Rizatriptan versus rizatriptan plus rofecoxib versus rizatriptan plus tolfenamic acid in the acute treatment of migraine. BMC Neurol.4, 10 (2004).
   PubMed Web of Science ®Google Scholar
• Krymchantowski AV. Naproxen sodium decreases migraine recurrence when administered with sumatriptan. Arq. Neuropsiquiatr.58, 428–430 (2000).
   PubMed Web of Science ®Google Scholar
• Krymchantowski AV, Adriano M, Fernandes D. Tolfenamic acid decreases migraine recurrence when used with sumatriptan. Cephalalgia19, 186–187 (1999).
   PubMed Web of Science ®Google Scholar
• Brandes JL, Kudrow D, Stark SR et al. Sumatriptan–naproxen for acute treatment of migraine: a randomized trial. JAMA297, 1443–1454 (2007).
   PubMed Web of Science ®Google Scholar
• Silberstein SD, Mannix LK, Goldstein J et al. Multimechanistic (sumatriptan–naproxen) early intervention for the acute treatment of migraine. Neurology71, 114–121 (2008).
   PubMed Web of Science ®Google Scholar
• Bou J, Gras J, Cortijo J et al. Vascular effects of the new anti-migraine agent almotriptan on human cranial and peripheral arteries. Cephalalgia21, 804–812 (2001).
   PubMed Web of Science ®Google Scholar
• Dowson AJ, Charlesworth BR. Patients with migraine prefer zolmitriptan orally disintegrating tablet to sumatriptan conventional oral tablet. Int. J. Clin. Pract.57, 573–576 (2003).
   PubMed Web of Science ®Google Scholar
• Loder E, Brandes JL, Silberstein S et al. Preference comparison of rizatriptan ODT 10-mg and sumatriptan 50-mg tablet in migraine. Headache41, 745–753 (2001).
   PubMed Web of Science ®Google Scholar
• Lainez MJ, Evers S, Kinge E et al. Preference for rizatriptan 10-mg wafer vs. eletriptan 40-mg tablet for acute treatment of migraine. Cephalalgia26, 246–256 (2006).
   PubMed Web of Science ®Google Scholar
• Ferrari MD, Goadsby PJ, Lipton RB et al. The use of multiattribute decision models in evaluating triptan treatment options in migraine. J. Neurol.252, 1026–1032 (2005).
   PubMed Web of Science ®Google Scholar
• Dodick DW, Lipton RB, Ferrari MD et al. Prioritizing treatment attributes and their impact on selecting an oral triptan: results from the TRIPSTAR Project. Curr. Pain. Headache Rep.8, 435–442 (2004).
   PubMedGoogle Scholar
• Rapoport AM, Mathew NT, Silberstein SD et al. Zolmitriptan nasal spray in the acute treatment of cluster headache: a double-blind study. Neurology69, 821–826 (2007).
   PubMed Web of Science ®Google Scholar
• Brandes JL, Kudrow D, Cady R et al. Eletriptan in the early treatment of acute migraine: influence of pain intensity and time of dosing. Cephalalgia25, 735–742 (2005).
   PubMed Web of Science ®Google Scholar
• Cady R, Martin V, Mauskop A et al. Efficacy of rizatriptan 10 mg administered early in a migraine attack. Headache46, 914–924 (2006).
   PubMed Web of Science ®Google Scholar
• Poolsup N, Leelasangaluk V, Jittangtrong J et al. Efficacy and tolerability of frovatriptan in acute migraine treatment: systematic review of randomized controlled trials. J. Clin. Pharm. Ther.30, 521–532 (2005).
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Zanchin G, Geraud G et al. Early vs. non-early intervention in acute migraine-’Act when Mild (AwM)’. A double-blind, placebo-controlled trial of almotriptan. Cephalalgia28, 383–391 (2008).
   PubMed Web of Science ®Google Scholar
• Linde M, Mellberg A, Dahlof C. Subcutaneous sumatriptan provides symptomatic relief at any pain intensity or time during the migraine attack. Cephalalgia26, 113–121 (2006).
   PubMed Web of Science ®Google Scholar
• Edvinsson L, Mulder H, Goadsby PJ, Uddman R. Calcitonin gene-related peptide and nitric oxide in the trigeminal ganglion: cerebral vasodilatation from trigeminal nerve stimulation involves mainly calcitonin gene-related peptide. J. Auton. Nerv. Syst.70, 15–22 (1998).
   PubMedGoogle Scholar
• Brain SD, Grant AD. Vascular actions of calcitonin gene-related peptide and adrenomedullin. Physiol. Rev.84, 903–934 (2004).
   PubMed Web of Science ®Google Scholar
• Levy D, Burstein R, Strassman AM. Calcitonin gene-related peptide does not excite or sensitize meningeal nociceptors: implications for the pathophysiology of migraine. Ann. Neurol.58, 698–705 (2005).
   PubMed Web of Science ®Google Scholar
• Doods H. Development of CGRP antagonists for the treatment of migraine. Curr. Opin. Investig. Drugs2, 1261–1268 (2001).
   PubMedGoogle Scholar
• Doods H, Hallermayer G, Wu D et al. Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist. Br. J. Pharmacol.129, 420–423 (2000).
   PubMed Web of Science ®Google Scholar
• Petersen KA, Lassen LH, Birk S et al. BIBN4096BS antagonizes human α-calcitonin gene related peptide-induced headache and extracerebral artery dilatation. Clin. Pharmacol. Ther.77, 202–213 (2005).
   PubMed Web of Science ®Google Scholar
• Olesen J, Diener HC, Husstedt IW et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N. Engl. J. Med.350, 1104–1110 (2004).
   PubMed Web of Science ®Google Scholar
• Ho TW, Mannix LK, Fan X et al. Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology70, 1304–1312 (2008).
   PubMed Web of Science ®Google Scholar
• Ho TW, Ferrari MD, Dodick DW et al. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet372, 2115–2123 (2008).
   PubMed Web of Science ®Google Scholar
• Ramadan NM, Buchanan TM. New and future migraine therapy. Pharmacol. Ther.112, 199–212 (2006).
   PubMed Web of Science ®Google Scholar
• Jhee SS, Shiovitz T, Crawford AW, Cutler NR. Pharmacokinetics and pharmacodynamics of the triptan antimigraine agents: a comparative review. Clin. Pharmacokinet.40, 189–205 (2001).
   PubMed Web of Science ®Google Scholar